AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.

On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Revolution Medicines, Inc. (NASDAQ:RVMD) has been making waves in the biotechnology sector with its innovative approach to ...

This study presents a valuable finding on the role of secretory leukocyte protease inhibitors (SLPI) in developing Lyme disease in mice infected with Borrelia burgdorferi. The evidence supporting the ...

Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of CD8+ CXCR3+ T cells offers potential for a first-in-class targeted systemic ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on BBIO stock, giving a Buy rating yesterday.Stay Ahead of the ...

The market is clearly trying to recover. Despite this, it means there will be a direct impact on the Chemicals and Materials industries. resulting in a large market for Global Water Treatment ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus's ...

A recent study evaluates the potential of Nanosota-EB1 and Nanosota-EB2, nanobody inhibitors targeting the Ebola virus.